Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with
chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver
fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven
significant fibrosis (METAVIR fibrosis stage ≥ F2). All enrolled subjects will be treated
with TAF monotherapy for 96 weeks. After 96 weeks of therapy, the second liver biopsy will be
performed to evaluate the rate of liver fibrosis regression. During this study, all subjects
will be assessed for laboratory tests, imaging examination at baseline, first 12-week and
every 24-week during follow-up.
Phase:
Phase 4
Details
Lead Sponsor:
Jidong Jia
Collaborators:
Beijing Ditan Hospital Huashan Hospital Ruijin Hospital Shanghai East Hospital ShuGuang Hospital The Sixth Peoples Hospital of Zhengzhou Tianjin Second People's Hospital Tianjin Third Central Hospital